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Abstract Phase I pharmacokinetic (PK) study assessed
circulating estrogens in breast cancer (BC) patients on a
non-steroidal aromatase inhibitor (NSAI) with vaginal
atrophy using vaginal ultra-low-dose 0.03 mg estriol (E3)
and Lactobacillus combination vaginal tablets (Gynoflor).
16 women on NSAI with severe vaginal atrophy applied a
daily vaginal tablet of Gynoflor for 28 days followed by a
maintenance therapy of 3 tablets weekly for 8 weeks.
Primary outcomes were serum concentrations and PK of
E3, estradiol (E2), and estrone (E1) using highly sensitive
gas chromatography–mass spectrometry. Secondary out-
comes were clinical measures for efficacy and side effects;
microscopic changes in vaginal epithelium and microflora;
and changes in serum FSH, LH, and sex hormone-binding
globulin. Compared with baseline, serum E1 and E2 did
not increase in any of the women at any time following
vaginal application. Serum E3 transiently increased after
the first application in 15 of 16 women, with a maximum of
168 pg/ml 2–3 h post-insertion. After 4 weeks, serum E3
was slightly increased in 8 women with a maximum of
44 pg/ml. The vaginal atrophy resolved or improved in all
women. The product was well tolerated, and discontinua-
tion of therapy was not observed. The low-dose 0.03 mg
E3 and Lactobacillus acidophilus vaginal tablets applica-
tion in postmenopausal BC patients during AI treatment
suffering from vaginal atrophy lead to small and transient
increases in serum E3, but not E1 or E2, and therefore can
be considered as safe and efficacious for treatment of
atrophic vaginitis in BC patients taking NSAIs.
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Introduction
Estrogen deprivation with oral aromatase inhibitors (AI) is
an established therapy in postmenopausal women with an
estrogen (ER) and/or progesterone receptor (PR) positive
breast cancer (BC) [1]. Although they improve survival,
AIs worsen or induce vaginal atrophy, dryness, and dys-
pareunia in most women [2]. Some develop atrophic vag-
initis, a subtype of aerobic vaginitis (AV) [3]. These side
effects dramatically reduce the quality of life (QoL) and
hamper compliance which affects patient survival [4]. As
more women using AI therapy are surviving BC for many
years, these side effects become a major challenge for both
patients and their physicians [5, 6].
Vaginal estrogen application is the most effective ther-
apy to alleviate these symptoms [4, 7, 8] and is clearly
more efficacious than non-hormonal therapies [9–11].
However, vaginal administration of any dose of
estradiol (E2) in AI users increases serum levels of
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E21 [3–14] [15–18]. Therefore, most authors see such
treatment as a potential danger in women with a history of
BC women as systemic absorption of estrogen can stimulate
the growth of breast cancer cells [5, 6, 19–22]. Thus, since
safety is a major issue, only less potent estrogens should be
considered for vaginal treatment. E3, a less potent estrogen
than E2, the vaginal application of 1 mg in postmenopausal
women with vaginal atrophy did not increase serum levels at
2 weeks, 3 months, and 6 months as compared to controls,
and endometrial biopsies showed no proliferation [23].
Gynoflor contains 10 [8] viable lyophilized Lactoba-
cillus acidophilus (L. acidophilus KS400) bacteria and
0.03 mg E3, which is a 16–32 times lower dose than in
conventional E3 vaginal preparations (0.5–1 mg). This
product has been proven to be safe and efficacious in res-
toration of the disturbed vaginal flora [24, 25] and in
treatment of postmenopausal atrophic vaginitis [26–29].
Former data indicate that application of one tablet of Gy-
noflor daily in healthy postmenopausal women with
vaginal atrophy doubles Cmax of E3 of compared with
baseline level, but still within the postmenopausal range at
day 1; whereas at day 12, Cmax compared with baselevel
was not increased at all [30].
This phase I pharmacokinetic study primarily assessed
circulating estrogens and efficacy after vaginal ultra-low-
dose 0.03 mg estriol (E3) and L. acidophilus combination
vaginal tablets (Gynoflor) in BC patients on a NSAI.
Subjects and methods
This was an open label bicentric phase I pharmacokinetic
(PK) study, in 16 postmenopausal women on a NSAIs and
suffering from symptomatic vaginal atrophy. This clinical
trial was conducted at two centers: one in Belgium and one
in Germany, and patients were included from April 2011
until July 2012. The study was approved by both the Ethical
Committees (IEC) and the national authorities as appro-
priate (EudraCT No: 2010-022007-22) and all patients
signed informed consent before any study action was taken,
according to GCP and the declaration of Helsinki. Hormone
analysis was performed by Nuvisan GmbH, Germany;
vaginal smear analysis was made by Femicare vzw, Bel-
gium, and a PK statistics—by Arlenda SA, Belgium. This
report complies with the CONSORT guidelines.
Included women were postmenopausal at an age of
52 years or more or C46 years after bilateral oophorec-
tomy with cessation of menses for at least 12 months and
started AI at least 6 months ago. Furthermore, in women
after hysterectomy with intact ovaries, FSH levels had to
be above 30 IU/l. Additional criteria were the presence of
clinical symptoms of vaginal atrophy, vaginal pH [ 5.0,
and a Karnofsky score C 80 %.
Main exclusion criteria were use of any other sex hor-
mones or phytoestrogens 6 months before or during the
study, use of any other vaginal medication, use of anti-
infectives, and use of steroidal AIs, sexually transmitted
infections or malignant or pre-cancerous conditions.
Women with a BMI lower than 18.5 or higher than 30 were
also excluded.
Gynoflor vaginal tablets (100 million viable L. aci-
dophilus KS400 and 0.03 mg E3) were supplied by Med-
inova AG, Switzerland. Recruited women underwent an
initial treatment for 4 weeks (1 vaginal tablet inserted daily
deep into the vagina before sleep and on PK testing days—
at entry and at visit after 4 weeks—early in the morning)
followed by maintenance therapy (3 vaginal tablets weekly
with one every second day) for 8 weeks.
The primary aim was to determine the absorption and
PK parameters of E3 and its influence on the serum con-
centrations of E2 and E1 during initial daily therapy.
Secondary goals were to test serum levels of E3, FSH,
luteinizing hormone (LH), and sex hormone-binding
globulin (SHBG), and also to evaluate clinical symptoms
and changes in the physiological status of the vaginal
epithelium and microflora, to compare the treatment suc-
cess during initial and maintenance therapy, and to assess
the safety profile.
Clinical examinations were performed at screening
(S = week–1), at entry (E = Day 0), and at days 14
(C1 = week 2), 28 (C2 = week 4), 56 (C3 = week 8),
and 84 (C4 = week 12) to assess hormone levels, efficacy,
and safety (Fig. 1).
Multiple blood samples for PK parameters were taken
at visit E and C2 at 0.5 h before and 0.5, 1, 2, 3, 4, 6, 8,
and 24 h after test drug application. In addition, at each
visit, samples were taken for testing of trough serum
levels of E3, E2, and E1 and concentrations of FSH, LH,
and SHBG.
Estrogens were analyzed using a highly sensitive gas
chromatography–mass spectrometry (GC/MS) method
(validated according to FDA Guidance for industry). After
extracting, cleaning-up, and derivation of 1 ml of serum,
1–2 ll of sample was injected into the GC/MS system.
Measurements were performed in the chemical ionisation
mode with negative ions using ammonia as reagent gas.
The lower limits of quantitation (LLOQ) were 10.00 pg/ml
for E3, 1.00 pg/ml for E2, and 2.00 pg/ml for E1. The
coefficient of variation (CV, intra-assay variation) was
2.0 % for E3 (calibration range (CR) 10.00–500.00 pg/),
4.2 % for E2 (CR 1.00–150.00 pg/ml), and 3.4 % for E1
(CR 2.00–300.00 pg/ml). FSH, LH, and SHBG measure-
ments were performed using automated immunoassay
analyser system Access by Beckman Coulter Inc., USA
following basic principle of a competitive immunoenzy-
matic binding assay.
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The primary efficacy parameters were serum concen-
trations of E3, E2, and E1, and E3 PK parameters on days 0
(visit E) and 28 (visit C2). The trough E3, E2, and E1
levels were pre-dose concentrations (-0.5 h) at control
visits. Concentrations below the LLOQ were considered as
zero in descriptive statistics. The area under the curve from
administration to the last measured concentration
(AUC0–24) was calculated by linear trapezoidal integration.
The highest measured concentrations were reported as
Cmax. Peak times evaluated as following: tmax,E = the time
at which the Cmax,E occur at visit E, and tmax,C2 = the time
at which the Cmax,C2 occur at visit C2.
The secondary parameters were trough serum concen-
trations of E3, E2, E1, FSH, LH, and SHBG at all visits;
vaginal pH; clinical symptoms (vaginal dryness, vaginal
soreness, dyspareunia, and feeling of vaginal discharge)
and clinical signs (paleness of the vagina, increased red-
ness of the vaginal walls, ulcerations, and decreased
vaginal rugae/mucosal plicae); and the physiological
parameters of the vaginal epithelium and microflora, and
efficacy, and safety. Vaginal smear samples (wet mount)
were taken from the right and left lateral vaginal walls
with an Ayre spatula, spread onto two slides, air-dried,
and centrally analyzed. The slides were used for imme-
diate pH reading and for microscopic evaluation of the
vaginal maturation index (VMI), lactobacillary grade
(LBG), bacterial vaginosis (BV) score, AV score, and the
presence of Candida. The vaginal pH was measured using
Macherey–Nagel pH strips as this provides superior and
easy reading [31]. The VMI was calculated based on the
percentages of superficial (X3) and intermediate (X2)
epithelial cells present in the vaginal smear according to
the formula [VMI = 0.5(X2) ? 1(X3)]. The vaginal
smears for the LBG, BV, and AV score were evaluated in
a standardized way, using a phase contrast Leica LM 28
microscope at 400 times magnification as described
elsewhere [3, 32, 33]. All slides were anonymized, and
randomly read by a person blinded to any clinical infor-
mation. At each control visit, the global efficacy was
assessed by both investigator and patient.
All women receiving at least one dose of study medi-
cation were included into the safety analysis set (SAF) and
evaluated for adverse events (AEs) or adverse drug reac-
tions (ADRs), and tolerability (by investigator and patient).
Clinical symptoms and medication compliance were
recorded in patient’s diary and in sexual questionnaire.
Treatment compliance was assessed by asking woman
about the medication, checking the medication, and by
reviewing the diaries.
The PK variables Cmax and AUC0–24 were ln-trans-
formed and then compared between day 28 (visit C2) and
day 0 (visit E) using a one-way analysis of variance. For
concentration-related PK parameters, the geometric mean
(GeoMean) was reported and in accordance with the mul-
tiplicative model, the coefficient of variation of the geo-
metric mean was calculated as GeoCV = [exp(r2) - 1],
with r2 = variance of ln-transformed data. The individual
subject values and PK parameters were tabulated with
descriptive statistics. Analyses of variance (ANOVA) were
performed on AUC0–24 and Cmax. All PK analyses related
to endpoints were performed using a validated software
(SAS version 9.2 by SAS Institute, USA). All other vari-
ables were analyzed descriptively. Values between visits
were compared using the Wilcoxon signed rank sum test,
the McNemar test, or the sign test. All continuous param-
eters were summarized using standard summary statistics
as appropriate. All subjects of the SAF set were included in
a per-protocol set (PPS) if they completed the study and
had no major protocol violations. Adverse events (AEs)
were tabulated by MedDRA, and the number and rate of
affected subjects were reported. The global assessment of
tolerability was reported too.
Results
From 19 screened women, 16 were included in this study, 8
from each center (Fig. 1). One protocol violation was
noted: a woman was treated with the steroidal AI exe-
mestane before switched to non-steroidal AI, but was
recruited as the investigator was not aware of that. Minor
protocol deviations included small shifts from PK mea-
surements schedule, PK sample processing, and shifts in
the visits schedule due to inability of patients to attend.
Fig. 1 Study design. At screening, eligible patients were included. At
Entry visit, an initial tablet of g-Gynoflor was introduced and a PK
study to detect serum estrogens over a 24 h period was performed
(Visit E). Patients were checked at 2 weeks for serum estrogen levels,
vaginal responses, and side effects (1). At day 28 (Visit C2), 56 (Visit
C3), and 84 (Visit C4), the same variables were checked, but on day
28 (Visit C2) another 24 h PK study for serum estrogen dynamics was
performed. Between visit E and visit C2 patients applied 1 vaginal
tablet daily (Initial therapy phase), whereas after visit 2 Gynoflor
was used every second day (Maintenance phase)
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All 16 patients were Caucasian, with a mean age of 57.0
(range 52.0–63.0) years and a body mass index of
23.5 ± 3.0. Patients menstruated a mean of 75.0 (range
25.0–277.0) months ago. The diagnosis of BC had been a
median of 2.6 years ago with a range from 2.0 to
28.2 years, and median duration of AI therapy was
2.1 years with a range of 0.5–7.7 years. The daily AI dose
was either 1 mg letrozole or 2.5 mg anastrozole. Mean
Karnofsky score was 98.1 ± 5.4 %. Mostly used con-
comitant medications were taken for gastrointestinal tract
illnesses (56 %) and for improving the function of the
musculoskeletal system, mainly antiphlogistics (44 %).
Treatment compliance was very good during both initial
(range 98.7–100.0 %) and maintenance therapy (range
95.8–100.0 %).
Serum E2 and E1 concentrations did not increase at
visit E and at visit C2 and were always below the LLOQ,
Fig. 2 Estriol (E3) pharmacokinetics (PK) on visit E (day 0) and
visit C2 (day 28); (PPS, n = 16)
Table 1 Average serum estriol
(E3) concentrations at Visit E
(day 0) and Visit C2 (day 28),
(PPS, n = 16)
Lower limit of quantitation
(LLOQ) considered as zero
(E3 \ 10.00 pg/ml)
SD Standard deviation
Visit Statistics Time after application (h)
-0.5 0.5 1 2 3 4 6 8 24
Visit E (day 0) Mean 0.00 3.83 11.04 72.73 84.35 28.29 0.00 0.00 0.00
Median 0.00 0.00 14.10 69.55 83.80 26.15 0.00 0.00 0.00
Minimum 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Maximum 0.00 14.10 18.80 168.00 160.00 67.50 0.00 0.00 0.00
SD 0.00 5.74 6.66 49.11 43.77 18.64 0.00 0.00 0.00
Visit C2 (day 28) Mean 0.91 1.58 1.55 1.96 2.48 3.12 7.33 10.23 0.00
Median 0.00 0.00 0.00 0.00 0.00 0.00 0.00 6.60 0.00
Minimum 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Maximum 14.50 12.90 14.40 16.60 29.20 37.70 39.50 43.70 0.00
SD 3.51 4.05 4.16 5.20 7.35 9.40 12.26 12.33 0.00
Table 2 Main pharmacokinetic (PK) parameters of E3 (PPS, n = 16)
Statistics Visit E Visit C2
Cmax,E (pg/ml) tmax,E (h) AUC(0–24),E (h * pg/ml) Cmax,C2 (pg/ml) tmax,C2 (h) AUC(0–24),C2
a (h * pg/ml)
n 16 15 16 16 8 15
Mean 104.5 2.5 212.5 15.8 7.2 130.7
SD 40.9 0.5 93.2 13.9 1.5 147.2
CV (%) 39.2 19.9 43.9 87.8 20.3 112.6
Minimum \LLOQ 2.0 \LLOQ \LLOQ 4.0 \LLOQ
Median 109.7 2.2 240.7 9.1 7.9 116.8
Maximum 168.0 3.1 378.0 43.7 8.0 457.0
GeoMean 88.2 NA 154.3 11.0 NA 19.9
GeoCV (%) 97.4 NA 223.4 107.5 NA 3805.1
a AUC(0–24),C2 parameter is not reliable due to late metabolism and insufficient testing points
n Number of patients, SD standard deviation, CV coefficient of variation, GeoMean geometric mean, GeoCV coefficient of variation of the
geometric mean, PPS per-protocol-set, Cmax maximal concentration, tmax time at which Cmax was reached, AUC (0–24) area under the curve from the
administration to the last measured concentration, NA not applicable, LLOQ lower limit of quantitation, considered as zero (E3 \ 10.00 pg/ml)
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except for one sample of one subject with a E2 concen-
tration just above LLOQ (1.19 pg/ml). After the first
application of test medication (visit E, day 0), 15 of 16
women had a transient increase in serum E3 concentration
with a Cmax ranging from 67.6 to 168.0 pg/ml, occurring at
2–3 h post-insertion (Fig. 2). This increase was much
Table 3 Secondary variables (PPS)
Variable Statistics Visits
E C1 C2 C3 C4
Hormones n 16 15 16 16 16
E3 baseline and trough (pg/ml) Mean (SD) 0.00 5.11 (14.01)a 0.91(3.63) 0.00 0.00
Minimum 0.00 0.00 0.00 0.00 0.00
Maximum 0.00 49.20 14.50 0.00 0.00
FSH (mIU/ml) Mean (SD) 107.88 (48.62) 103.71 (39.76) 98.94 (34.95) 103.55 (37.53) 105.93 (43.69)
Minimum 45.50 38.30 41.00 41.60 43.00
Maximum 257.00 198.00 184.00 187.00 230.00
LH (mIU/ml) Mean (SD) 36.46 (11.05) 34.52 (12.18) 34.02 (12.68) 34.2 (49.87) 35.13 (10.34)
Minimum 22.80 15.10 18.60 16.60 19.90
Maximum 67.00 69.10 65.10 58.00 61.20
SHBG (nmol/l) Mean (SD) 73.04 (29.66) 74.24 (35.35) 71.29 (31.88) 73.35 (32.76) 72.43 (34.57)
Minimum 27.30 27.70 32.90 33.00 31.30
Maximum 148.00 175.00 176.00 166.00 173.00
VMI (%) n 15 16 16 16 16
Mean (SD) 31.2 (19.4) 69.9 (13.6) 71.6 (15.1) 78.0 (16.0) 72.8 (17.8)
Minimum 2.5 41.5 44.5 33.0 42.5
Maximum 79.0 91.0 95.0 95.5 100.0
LBG [I = 1, IIa = 2, IIb = 3, III = 4] n 14 16 16 16 16
Mean (SD) 3.9 (0.3) 1.9 (0.7) 1.9 (0.6) 1.3 (0.6) 1.4 (0.8)
Vaginal pH n 16 16 16 16 16
Mean (SD) 6.0 (0.3) 4.6 (0.5) 4.4 (0.4) 4.6 (0.5) 4.5 (0.5)
Vaginal symptoms n 16 16 16 16 16
Dryness [10-point scale] Mean (SD) 7.4 (2.3) 4.9 (2.0) 3.9 (2.6) 3.5 (2.7) 3.2 (3.2)
Soreness [10-point scale] Mean (SD) 5.9 (3.2) 2.1 (2.1) 1.5 (2.0) 1.8 (2.3) 1.9 (3.1)
Discharge [10-point scale] Mean (SD) 0.6 (1.6) 5.1 (3.1) 3.9 (2.4) 3.1 (2.5) 2.6 (2.5)
Dyspareunia [10-point scale] Mean (SD) n 6.3 (4.2) 4 5.3 (4.5) 7 4.0 (3.5) 7 3.9 (3.2) 7 3.4 (4.0) 7
Vaginal signs n 16 16 16 16 16
Paleness [yes = 1, no = 0] Mean (SD) 0.8 (0.5) 0.3 (0.5) 0.3 (0.5) 0.3 (0.5) 0.1 (0.3)
Redness [yes = 1, no = 0] Mean (SD) 0.3 (0.5) 0.2 (0.4) 0.4 (0.5) 0.3 (0.5) 0.4 (0.5)
Ulceration [yes = 1, no = 0] Mean (SD) 0.1 (0.3) 0.0 0.0 0.1 (0.3) 0.0
Decreased rugae [no = 0, yes = 1] Mean (SD) 0.5 (0.5) 0.3 (0.5) 0.3 (0.5) 0.1 (0.3) 0.2 (0.4)
Microscopy n 14 16 16 16 16
BV score [scores 0–2] Mean (SD) 0.1 (0.4) 0.0 0.3 (0.5) 0.1 (0.3) 0.1 (0.3)
AV score [scores 0–10] Mean (SD) 7.0 (2.0) 2.3 (1.6) 1.8 (1.6) 0.9 (1.3) 0.8 (1.5)
Candida [yes = 1, no = 0] Mean (SD) 0.1 (0.4) 0.4(0.5) 0.2 (0.4) 0.2 (0.4) 0.1 (0.3)
Efficacy [4-1, 1 = very good] n 16 16 16 16
Investigator Mean (SD) 1.7 (0.6) 1.7 (0.6) 1.7 (0.6) 1.4 (0.6)
Patient Mean (SD) 2.1 (0.9) 1.9 (0.7) 1.7 (0.7) 1.3 (0.6)
Tolerability [4-1, 1 = very good] n 16 16 16 16
Investigator Mean (SD) 1.5 (0.5) 1.8 (0.8) 1.6 (0.6) 1.4 (0.6)
Patient Mean (SD) 1.6 (0.8) 1.5 (0.7) 1.6 (0.6) 1.4 (0.6)
a n = 14, PPS per-protocol set, n number of patients, SD standard deviation, FSH follicle stimulating hormone, LH luteinising hormone, SHBG
sex hormone-binding globulin, VMI vaginal maturation index, LBG lactobacillary grade, BV bacterial vaginosis, AV aerobic vaginitis, E entry
visit, C control visits
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lower (maximum 43.70 pg/ml) and occurred later (at
6–8 h) after 4 weeks (visit C2, day 28) and at this visit half
of the subjects did not have at all any quantifiable con-
centrations of E3 (Table 1). The Cmax (Table 2) was sig-
nificantly lower at visit C2 compared to visit E
(p \ 0.0001).
E3 levels (Table 3; Fig. 3) were below the LLOQ for
all, except two subjects. One had a E3 serum concentration
of 22.3 pg/ml at C1, and one had E3 levels of 49.2 pg/ml
and 14.5 pg/ml at C1 and C2, respectively. The trough
concentrations for E2 and E1 were always below LLOQ.
There were no statistically significant changes of LH
and SHBG serum concentrations during treatment. At
visit C2, FSH showed a scant, but significant decrease of
serum concentration compared to E (p = 0.025), but no
significant differences were observed at visits C1, C3, and
C4.
VMI improved rapidly already after 2 weeks of treat-
ment from 31 % at entry to 70 % at visit C1 (p \ 0.0001)
and to 72 % at the end of initial therapy, and was main-
tained until the end of maintenance therapy at 73 %
(Fig. 4, panel a).
Maximum E3 levels inversely correlated with VMI
values at visit E and visit C2 (R2 = 0.62, Fig. 5), demon-
strating that the maturing epithelium rapidly precludes
further E3 absorption after the initial therapy.
Another important efficacy variable was LBG. At the
study entry, the majority of subjects had grossly abnormal
vaginal flora (LBG III, 81 %), the remainder being LBG
IIb (moderately disturbed). After the 28 days of therapy,
almost complete normalisation of the vaginal flora was
observed (Fig. 4, panel b): it had become only slightly
disturbed (LBGIIa, 63 %) or normal (LBGI, 25 %). Further
significant improvements were observed during the main-
tenance therapy: at C4, the majority of women had a stable
and normal vaginal flora (LBGI, 69 %; p = 0.039).
Vaginal pH showed statistically significant decrease
(Fig. 4, panel c) from entry (mean 6.0) to visits C1, C2, and
C4 (mean 4.4–4.6; p \ 0.001), and remained unchanged
thereafter during maintenance therapy.
Clinical symptoms of vaginal atrophy like dryness,
soreness, and dyspareunia all improved during treatment.
Dryness and soreness improved dramatically from entry to
control visits (p \ 0.001), while statistical evaluation of
the improvement in dyspareunia was hampered by low
numbers. At entry, sexual intercourse was reported only by
19 % of women, whereas 31 % reported intercourse at visit
C4 (p [ 0.05). The experience of vaginal discharge
increased significantly from entry to C2 (p \ 0.01), and
then decreased to the end of treatment. Vaginal paleness
Fig. 3 Baseline/trough estrogen levels (PPS, n = 16)
Fig. 4 Vaginal characteristics during the entry and follow-up phases
of the study
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improved significantly from entry to C2 (p = 0.039) and to
C4 (p = 0.006), whereas for redness, ulceration, and rugae,
no significant improvement was observed (Table 3).
Almost no women had BV flora at any visit, except at
visit C2, where 4 subjects (25 %) presented with partial
BV flora (p [ 0.05). AV score substantially improved
during treatment, from 81 % of patients had moderate to
severe AV at entry, to only 37 % with light to moderate
AV after initial therapy (p \ 0.001). After maintenance
therapy, all except one women had returned to normal flora
(p \ 0.001). The majority of subjects had no Candida
colonization at either visit (75–88 %), but at visit C1, 7
women (44 %) were colonized and 4 of them remained
colonized during further visits.
From the second week of treatment, the majority of
investigators and patients assessed the efficacy as good or
very good ([90 and [75 %, respectively) and the evalua-
tions of efficacy by patient significantly increased during
maintenance therapy to 94 % at the end of the study period
(p = 0.022, Table 3). Global tolerability of the treatment
was assessed by both the investigator and patient as good
or very good (81–100 %).
No serious AE was reported. All 40 AEs were of mild or
moderate severity, of which 15 (62.5 %) were assessed as
potentially related to the study medication. The most fre-
quent of them was vaginal discharge.
Discussion
Currently, it is not possible to determine the safety of
vaginal estrogen treatment on the basis of data from clin-
ical studies which examine its effect on breast cancer
recurrences. Therefore, systemic estrogen absorption and
efficacy of intravaginal ultra-low-dose 0.03 mg E3
combined with lactobacilli for vaginal atrophy were tested
in a unique study in postmenopausal women on AI therapy.
The systemic estrogen levels in NSAI users are much lower
as compared to those in healthy postmenopausal women
[34]. The use of highly sensitive GC/MS and determining
minimal blood level changes of various estrogens are
crucial to prove safety in BC patients [35]. In order to
clarify this to clinicians taking care of breast cancer
patients, we emphasize that routine estrogen assays as they
are used in most clinical settings and hospitals are not
sufficiently sensitive to guarantee absence of harm due to
low levels of circulating estrogens.
In a study, comparing the absorption from a vaginal ring
or tablets with E2 in postmenopausal BC patients (no AI
therapy), serum levels of E2 and E1 were temporarily
raised and efficiently relieved vaginal atrophy [36]. In
another study, treatment with low-dose vaginal estrogen
(0.25 mg E3 or 12.50 lg E2 twice weekly, for 12 weeks),
no increase in E2 or E3 was noted, although no PK values
were determined [15]. Vaginal application of a conven-
tional 0.50 mg dose of E3 resulted in increased serum
levels of E3, but not E2 and E13 [8–39]. There is fear that
even a small, permanent increase in systemic serum
estrogen, particularly E1 and E2, may increase the risk of
BC recurrence [12, 19]. O’Meara and colleagues reported
in their case-controlled study that the risk of recurrence in
BC patients who used vaginal estrogens was not increased,
irrespective of the total dose and type of estrogen applied
[40]. In a study of 69 BC patients suffering from symptoms
of vaginal atrophy, vaginal E3 (n = 36) or vaginal E2
(n = 33) was used, with no detrimental effect on recur-
rence after years of follow-up [41]. A retrospective cohort
study in Finland showed that neither the use of vaginal E2
and E3 preparations nor oral E3 were associated with a risk
of BC in postmenopausal patients [42]. Hence, strong
recommendations either supporting or rejecting the use of
various vaginal estrogens in some postmenopausal BC
women on AIs are today still difficult to substantiate.
Obviously, not all physiologically available estrogens
have the same properties. Whereas E2 and E1 can be
reversibly metabolised into each other, E3 is an end product
of estrogen metabolism and cannot be transformed back into
either E1 or E2 [43, 44]. E3 has been shown to have a
10-times lower affinity to the nuclear ER as compared to E2
[44], and the nuclear retention time of the E3 receptor
complex is much shorter (\6 h) than that of the E2 receptor
complex ([12 h) [45]. This in combination with its low
affinity for plasma proteins and its rapid metabolic clearance
turns E3 into a short-acting estrogen [19]. Importantly, it has
been consistently reported that vaginal absorption of E3
decreases as the vaginal epithelium matures within a few
days to weeks after the start of vaginal treatment [30, 46, 47].
It also has been recognized that in order to exert any
Fig. 5 The highest estriol (E3) serum level after the tablet applica-
tion and the vaginal maturation index (VMI) has been compared.PPS
per-protocol-set, R2 coefficient of determination, VMI vaginal mat-
uration index, E3 estriol
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stimulatory effect on endometrial and breast tissues, con-
tinuous and high doses of E3 use are required [43].
The current study demonstrated that systemic absorption
of E3 after administration of Gynoflor was present, but
minimal and transient. After 28 days of vaginal tablet
application, most E3 concentrations were below the LLOQ.
The exposure (AUC0–24) as well as Cmax was significantly
lower at the end of initial therapy compared with study entry.
Trough serum E3, E2, and E1 concentrations remained
below their LLOQ for all but 2 patients, where slightly
higher levels of E3 were observed. For LH, FSH, and SHBG,
only small changes were observed. So, in order to conclude
that the application of Gynoflor in postmenopausal BC
patients is oncologically safe, it has to be determined whe-
ther this short transient increase of E3 has any influence on
BC cells? Although 15 of 16 patients showed this increase
after an initial application of Gynoflor, the absorption during
therapy decreased (Cmax decreases and tmax increases) as the
vaginal epithelium is becoming more mature, as reported in
earlier studies [30, 46, 47]. After 4 weeks, daily application
of vaginal E3 did not lead to detectable increases in 50 % of
patients. The maximum E3 levels were less than 45 pg/ml,
and in 25 % of women the highest detected level was
below 20 pg/ml. The clinical significance of such transient
increases of E3 serum levels is unknown, but probably
negligible. In the same period, we did not observe elevations
of E2 and E1 levels. In vitro investigations demonstrated that
both E2 and E3 can stimulate BC cells, but the effect largely
depends on their concentration and duration of action [48].
Hence, the slight and short-lived rise of E3 serum concen-
trations, without any detectable increase in E2 or E1, can
most likely be considered oncologically safe in BC women
on AIs. However, even though our observations from this
small phase I study are of interest, the ultimate safety of
treating women with ER positive breast cancer who are on
AIs with small doses of E3 must be demonstrated in larger,
properly conducted trials.
Despite the low total absorption of E3, the treatment with
ultra-low-dose E3 and lactobacilli combination demon-
strated an excellent efficacy: VMI, LBG, vaginal pH nor-
malised, and clinical symptoms of atrophy improved rapidly
and dramatically, both during the initial therapy and during
the subsequent maintenance therapy. Global efficacy was
good or very good, already after 2 weeks of treatment, and
improved further till the end of the study. In addition, patients
reported an improvement of QoL which is important in BC
patients, who frequently report loss of sexual interest and
enjoyment after start of anticancer treatment [49]. Gynoflor
was well tolerated. No serious AEs occurred during the
study, and none of the AEs were judged as severe.
The strengths of the study were the precise study design,
investigation of relevant parameters (PK, safety, and effi-
cacy) in the investigated patient population, and the use of
highly sensitive GC/MS to detect minimal changes of
systemic estrogen concentrations. The weaknesses of the
study were small numbers for testing of some parameters
(especially dyspareunia).
In conclusion, 0.03 mg E3 and L. acidophilus vaginal
tablets (Gynoflor) can be considered safe and efficacious
for treatment of atrophic vaginitis in BC patients taking
AIs. The initial daily vaginal tablet for 4 weeks followed
by one application every second day as maintenance ther-
apy led to small and transient increases in serum E3, but
not E1 or E2, and therefore seems to be safe in BC patients.
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